Trader Brian Jones@MasterBJonesJanuary 05, 2022 8:36 am ET Lixte Biotechnology's LB-100 Reported To Convert Immunologically Unresponsive Tumors To Immunologically Responsive Tumors1:47 PM · Jan 5, 2022·Twitter Web App1 Retweet20 Likes
